Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...

Sequential intravesical gemcitabine and docetaxel is associated with better oncologic outcomes compared with additional BCG in patients with BCG-unresponsive NMIBC and warrants a trial. Sequential ...

This study, known as ESPAC4, reported on with long-term follow-up of 732 patients in a phase 3, open-label, multicentre, randomised clinical trial of GemCap vs gemcitabine. Patients were seen in 92 ...

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer Patients with ...

Gloved hand holding infusion line. Source: Getty Images Investigators report significantly improved cancer-specific and overall survival. WASHINGTON, DC—Sequential intravesical gemcitabine-docetaxel ...

Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve ...

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX ...

The approval, which is based on results from the phase 3 KEYNOTE-966 trial, marks the sixth indication for pembrolizumab in gastrointestinal cancer. The FDA has approved pembrolizumab (Keytruda; Merck ...

A phase 2 study of neoadjuvant gemcitabine, cisplatin, plus nivolumab met its co-primary end point with a positive predictive value of clinical complete response of 0.97 among patients with ...

CARY, N.C.--(BUSINESS WIRE)--Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products today announced successful completion of the nonclinical ...